BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24391196)

  • 1. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
    Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
    J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
    Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
    Jentschke M; Soergel P; Hillemanns P
    J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.
    Depuydt CE; Benoy IH; Beert JF; Criel AM; Bogers JJ; Arbyn M
    J Clin Microbiol; 2012 Dec; 50(12):4073-7. PubMed ID: 23052314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of the BioPerfectus multiplex real time HPV assay for self-collected samples cervical cancer screening].
    Chen Q; Du H; Wang C; Hu QC; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):307-311. PubMed ID: 31154711
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
    Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
    J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
    Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
    BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.
    Avian A; Clemente N; Mauro E; Isidoro E; Di Napoli M; Dudine S; Del Fabro A; Morini S; Perin T; Giudici F; Cammisuli T; Foschi N; Mocenigo M; Montrone M; Modena C; Polenghi M; Puzzi L; Tomaic V; Valenti G; Sola R; Zanolla S; Vogrig E; Riva E; Angeletti S; Ciccozzi M; Castriciano S; Pachetti M; Petti M; Centonze S; Gerin D; Banks L; Marini B; Canzonieri V; Sopracordevole F; Zanconati F; Ippodrino R
    J Transl Med; 2022 May; 20(1):231. PubMed ID: 35581584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.
    Hesselink AT; Meijer CJ; Poljak M; Berkhof J; van Kemenade FJ; van der Salm ML; Bogaarts M; Snijders PJ; Heideman DA
    J Clin Microbiol; 2013 Jul; 51(7):2409-10. PubMed ID: 23637297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay.
    Borgfeldt C; Forslund O
    J Virol Methods; 2019 Aug; 270():18-20. PubMed ID: 31002831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening.
    Heideman DAM; Oštrbenk Valenčak A; Doorn S; Bonde J; Hillemanns P; Gimpelj Domjanič G; Mlakar J; Hesselink AT; Meijer CJLM; Poljak M
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
    Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
    J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Performance of the RealTi
    Latsuzbaia A; Vanden Broeck D; Van Keer S; Weyers S; Tjalma WAA; Doyen J; Donders G; De Sutter P; Vorsters A; Peeters E; Arbyn M
    Microbiol Spectr; 2022 Oct; 10(5):e0163122. PubMed ID: 36047900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.
    Saville M; Sultana F; Malloy MJ; Velentzis LS; Caruana M; Ip ELO; Keung MHT; Canfell K; Brotherton JML; Hawkes D
    J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.